Open AccessUpper Gastrointestinal Tract Safety Profile of Alendronate
Author(s) -
Douglas C. Bauer
Publication year - 2000
Publication title -
archives of internal medicine
Language(s) - English
Resource type - Journals
eISSN - 1538-3679
pISSN - 0003-9926
DOI - 10.1001/archinte.160.4.517
Subject(s) - medicine , placebo , gastroenterology , adverse effect , relative risk , randomized controlled trial , duodenum , alendronic acid , confidence interval , osteoporosis , bone mineral , pathology , alternative medicine
To determine whether alendronate sodium treatment is associated with upper gastrointestinal (GI) tract adverse experiences (AEs)-particularly those of the stomach, duodenum, or esophagus-in the Fracture Intervention Trial, and to assess the relationship between alendronate use and upper GI tract events among women at increased risk for these outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom